Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10114302 | 1.00 | MAPT (0.49) | MAPTALDH1A1MEN1KMT2ANAMPT | |
| SCHEMBL10114125 | 1.00 | MAPT (0.49) | MAPTALDH1A1MEN1KMT2ANAMPT | |
| SCHEMBL10113964 | 1.00 | MAPT (0.49) | MAPTALDH1A1MEN1KMT2ANAMPT | |
| SCHEMBL13204286 | 1.00 | MAPT (0.49) | MAPTALDH1A1MEN1KMT2ANAMPT | |
| SCHEMBL13204314 | 1.00 | MAPT (0.49) | MAPTALDH1A1MEN1KMT2ANAMPT | |
| SCHEMBL10114225 | 0.90 | MAPT (0.46) | MAPTALDH1A1MEN1KMT2ANPSR1 | |
| SCHEMBL14424268 | 0.90 | MAPT (0.46) | MAPTALDH1A1MEN1KMT2ANPSR1 | |
| SCHEMBL10114834 | 0.90 | MAPT (0.46) | MAPTALDH1A1MEN1KMT2ANPSR1 | |
| SCHEMBL13204368 | 0.89 | MAPT (0.45) | MAPTALDH1A1MEN1KMT2ANPSR1 | |
| SCHEMBL10134476 | 0.89 | MAPT (0.45) | MAPTALDH1A1MEN1KMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8115027-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2012-02-14 | — | — | US | disclosed |
| US-20100292500-A1 | NPY Y5 ANTAGONIST | KAWANISHI YASUYUKI | 2010-11-18 | — | — | US | disclosed |
| US-7265130-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2007-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292500-A1 | NPY Y5 ANTAGONIST | NPY5R, NPY1R, NPY2R | MAPT 3367/4885ALDH1A1 4599/4885MEN1 2932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.